Cut-off point of epicardial adipose tissue thickness for predicting metabolic syndrome in Venezuelan population

Lima-Martínez, Marcos M.; Paoli, Mariela; Donis, José H.; Odreman, Rodolfo; Torres, Christopher; Iacobellis, Gianluca

doi:10.1016/j.endoen.2013.12.007

Cited by 13 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epicardial fat is a marker of visceral fat. It has been also demonstrated to be an independent predictor of metabolic risk [26,27]. EAT thickness is greater in subjects with impaired fasting glucose [28] and insulin resistance [29].…”

Section: Discussionmentioning

confidence: 98%

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

Lima-Martínez

Paoli

Rodney³

et al. 2015

Endocrine

Self Cite

View full text Add to dashboard Cite

The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥ 7% on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆%) of -15% after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7%, respectively (p = 0.001 for all). After 6 month, EAT ∆% was significantly correlated with ∆% of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆% (r = 0.292; p = 0.147) or HbA1c ∆% was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.

show abstract

Section: Discussionmentioning

confidence: 98%

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

Lima-Martínez

Paoli

Rodney³

et al. 2015

Endocrine

Self Cite

View full text Add to dashboard Cite

show abstract

“…33,34 Additionally, less epicardial (ectopic) adipose tissue predicts MetS in individuals from Ciudad Bolívar (Guayana) and Mérida (Andeans) compared with data reported in whites. 35 Recently, a study with 2026 adults from Maracaibo, Venezuela, demonstrated a cutoff point of 2.00 for an updated HOMA (HOMA2-IR), which is lower than that reported in other populations. 36 Taken together, these data suggest that Venezuelans develop insulin resistance and accumulation of visceral fat earlier than other populations.…”

Section: R E S U L T S Causes and Factors Associated With Diabetes Inmentioning

confidence: 90%

Diabetes Care in Venezuela

Nieto-Martínez

González-Rivas

Lima-Martínez

et al. 2016

Annals of Global Health

View full text Add to dashboard Cite

Strategies to improve diabetes care in Venezuela include enhancing resources, reducing costs, improving education, implementing screening (using Latin America Finnish Diabetes Risk Score), promoting diabetes care units, avoiding insulin levels as diagnostic tool, correct use of oral glucose tolerance testing and metformin as first-line T2D treatment, and reducing health system fragmentation. Use of the Venezuelan adaptation of the transcultural Diabetes Nutrition Algorithm for lifestyle recommendations and the Latin American Diabetes Association guidelines for pharmacologic interventions can assist primary care physicians in diabetes management.

show abstract

“…Metabolic syndrome is a collection of many risk factors associated with CAD. Many studies are showing that EAT is increased significantly in a person with MS (11)(12)(13). The present study has determined that EAT in the MS group is significantly increased compared to the control group.…”

Section: Discussionmentioning

confidence: 44%

The Relationship between the Amount of Epicardial Adipose Tissue Measured on Echocardiography and Decreased Heart Rate Recovery in Exercise Stress Test in Patients with Metabolic Syndrome

Böyük¹,

Özdemi̇r²,

Güllülü³

2020

Ulutas Med J

View full text Add to dashboard Cite

IntroductionMetabolic Syndrome (MS) is a modern life disease in which multiple fatal systemic disorders such as glucose intolerance starting with insulin resistance or diabetes mellitus, obesity, hypertension, and coronary artery disease blend with each other. NHANES III study, carried out in the USA, reported MS incidence in the population of over 20 years of age was 34% and it was three-fold in the 40-59 age group compared to the 20-39 age (1).

show abstract

Cut-off point of epicardial adipose tissue thickness for predicting metabolic syndrome in Venezuelan population

Cited by 13 publications

References 29 publications

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

Diabetes Care in Venezuela

The Relationship between the Amount of Epicardial Adipose Tissue Measured on Echocardiography and Decreased Heart Rate Recovery in Exercise Stress Test in Patients with Metabolic Syndrome

Contact Info

Product

Resources

About